In this paper, we study a more general diffusive spatially dependent vaccination model for infectious disease. In our diffusive vaccination model, we consider both therapeutic impact and nonlinear incidence rate. Also, in this model, the number of compartments of susceptible, vaccinated and infectious individuals are considered to be functions of both time and location, where the set of locations (equivalently, spatial habitats) is a subset of with a smooth boundary. Both local and global stability of the model are studied. Our study shows that if the threshold level the disease-free equilibrium is globally asymptotically stable. On the other hand, if then there exists a unique stable disease equilibrium . The existence of solutions of the model and uniform persistence results are studied. Finally, using finite difference scheme, we present a number of numerical examples to verify our analytical results. Our results indicate that the global dynamics of the model are completely determined by the threshold value .
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17513758.2020.1849831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influenza B virus infection alters the regenerative potential of murine alveolar type 2 pneumocytes.
mBio
December 2024
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.
Unlabelled: Respiratory epithelial cells can survive direct infection by influenza viruses, and the long-term consequences of that infection have been characterized in a subset of proximal airway cell types. The impact on the cells that survive viral infection in the distal lung epithelia, however, is much less well-characterized. Utilizing a Cre-expressing influenza B virus (IBV) and a lox-stop-lox tdTomato reporter mouse model, we identified that alveolar type 2 (AT2) pneumocytes, a progenitor cell type in the distal lung, can survive viral infection.
View Article and Find Full Text PDFA phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies.
Clin Cancer Res
January 2025
Stanford University, Stanford, CA, United States.
Purpose: Activating T cell costimulatory receptors is a promising approach for cancer immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with SD101, a TLR9 agonist, was curative in a mouse model of lymphoma. We sought to test this combination in a Phase I clinical trial for patients with low-grade B cell lymphoma.
View Article and Find Full Text PDFmRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity against .
mSphere
December 2024
Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University, Chengdu, China.
is a prominent Gram-negative and encapsulated opportunistic pathogen that causes a multitude of infections such as severe respiratory and healthcare-associated infections. Despite the widespread anti-microbial resistance and the high mortality rate, currently, no clinically vaccine is approved for battling . To date, messenger RNA (mRNA) vaccine is one of the most advancing technologies and are extensively investigated for viral infection, while infrequently applied for prevention of bacterial infections.
View Article and Find Full Text PDFAge-Related Dynamics and Spectral Characteristics of the TCRβ Repertoire in Healthy Children: Implications for Immune Aging.
Aging Cell
January 2025
National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China.
T-cell receptor (TCR) diversity is crucial for adaptive immunity, yet baseline characterizations in pediatric populations remain sparse. We sequenced the TCRβ chain of 325 healthy Chinese children aged 0-18, categorized into six age groups. We also analyzed cellular composition and TCRβ associations using flow cytometry in 81 of these samples.
View Article and Find Full Text PDFA Surrogate BSL2-compliant Infection Model Recapitulating Key Aspects of Human Marburg Virus Disease.
Emerg Microbes Infect
January 2025
State Key Laboratory of Pathogenic Microorganisms, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Marburg virus disease (MVD) is a severe infectious disease characterized by fever and profound hemorrhage caused by the Marburg virus (MARV), with a mortality rate reaching 90%, posing a significant threat to humans. MARV lies in its classification as a biosafety level four (BSL-4) pathogen, which demands stringent experimental conditions and substantial funding. Therefore, accessible and practical animal models are urgently needed to advance prophylactic and therapeutic strategies for MARV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!